Why Drug Developers Choose IgG4 for Monoclonal Antibodies? – Illiasul Ibad
Illiasul Ibad, Rheumatologist at Christian Medical College, posted on X:
”1․ Why are many therapeutic monoclonal antibodies built on the IgG4 framework?
2․ Understand basics
Biology of IgG4
• Least abundant IgG subclass
• Very weak complement activation
• Poor interaction with Fc receptors → almost no ADCC
Translation: IgG4 can block targets without collateral tissue damage.
3․ Fab-arm exchange
Natural IgG4 can swap half its arms → becomes “functionally monovalent.”
Good for tolerance in nature, but bad for drug stability.
Solution: scientists engineered the S228P mutation → no swapping, molecule stays stable.
4․ Why drug developers love IgG4
• Precise blocking, not killing
• Low inflammation risk
• Engineered stability
• Safe for long-term therapy
That’s why IgG4 is the backbone of modern antibody medicines – quiet, stable, effective.”
Stay updated with Hemostasis Today.
-
Feb 27, 2026, 11:21Amelia Carro Hevia: Effect of Alirocumab on Coronary Plaque After MI
-
Feb 27, 2026, 11:14Dino Mehic: Completing the Missing Puzzle Pieces in VITT Pathogenesis
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President